SCHEMBL3547869

SCHEMBL3547869

CCN1CCC(NC(=O)c2ccc(Nc3ncc4c(n3)N(C3CCCC3)CC3(CC3)C(=O)N4C)c(OC)c2)CC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 16/20 0.74
BRD4 O60885 7/20 0.74
BRDT Q58F21 5/20 0.74
PLK3 Q9H4B4 5/20 0.67
RAD52 P43351 1/20 0.66
ALK Q9UM73 3/20 0.64
PRKD3 O94806 3/20 0.63
CLK2 P49760 3/20 0.63
PTK2 Q05397 3/20 0.63
CAMK2G Q13555 3/20 0.63
CAMK2D Q13557 3/20 0.63
PRKD2 Q9BZL6 3/20 0.63
CSNK1G1 Q9HCP0 3/20 0.63
CSNK1G3 Q9Y6M4 3/20 0.63
DAPK3 O43293 2/20 0.63
CHEK2 O96017 2/20 0.63
EGFR P00533 2/20 0.63
FES P07332 2/20 0.63
PHKG2 P15735 2/20 0.63
CSNK1D P48730 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541399 0.99 PLK1 (0.74) PLK1BRD4BRDTPLK3RAD52
SCHEMBL3542113 0.96 PLK1 (0.71) PLK1BRD4BRDTPLK3RAD52
SCHEMBL3541526 0.95 PLK1 (0.70) PLK1BRD4BRDTPLK3RAD52
SCHEMBL12879981 0.94 PLK1 (0.69) PLK1BRD4BRDTPLK3RAD52
SCHEMBL1203630 0.94 PLK1 (0.69) PLK1BRD4BRDTPLK3RAD52
SCHEMBL1203741 0.94 PLK1 (0.69) PLK1BRD4BRDTPLK3RAD52
SCHEMBL2397141 0.94 PLK1 (0.78) PLK1BRD4BRDTPLK3RAD52
SCHEMBL12880554 0.93 PLK1 (0.74) PLK1BRD4BRDTPLK3RAD52
SCHEMBL2401008 0.93 PLK1 (0.84) PLK1BRD4BRDTPLK3RAD52
SCHEMBL23025803 0.93 PLK1 (0.77) PLK1BRD4BRDTPLK3RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709471-B2 Compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-20080009482-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009482-A1 NOVEL COMPOUNDS CYP11B2, CYP11B1, CYP46A1 PLK1 847/4885BRD4 2662/4885BRDT 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.